Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT01548144
Title Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors M.D. Anderson Cancer Center

Advanced Solid Tumor


Crizotinib + Pazopanib

Crizotinib + Pemetrexed Disodium

Pazopanib + Pemetrexed Disodium

Crizotinib + Pazopanib + Pemetrexed Disodium

Age Groups: adult
Covered Countries USA

No variant requirements are available.